Cargando…

Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications

SIMPLE SUMMARY: Drugs targeting activating BRAF mutations have transformed the prognosis and treatment of MAPK-pathway-induced cancers. In neuro-oncology, the better knowledge of the MAPK pathway’s involvement in gliomagenesis offers hope in a subset of brain cancers where conventional therapies hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lhermitte, Benoit, Wolf, Thibaut, Chenard, Marie Pierre, Coca, Andres, Todeschi, Julien, Proust, François, Hirsch, Edouard, Schott, Roland, Noel, Georges, Guerin, Eric, Reita, Damien, Chammas, Agathe, Salmon, Alexandra, Martin, Sophie, Dontenwill, Monique, Entz-Werlé, Natacha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954401/ https://www.ncbi.nlm.nih.gov/pubmed/36831610 http://dx.doi.org/10.3390/cancers15041268

Ejemplares similares

LGG-16. Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.
por: Courant, Marie, et al.
Publicado: (2022)

DIPG-33. P16 IMMUNOHISTOCHEMICAL EXPRESSION AS A SURROGATE ASSESSMENT OF CDKN2A ALTERATION IN GLIOMAS LEADING TO PROGNOSTIC SIGNIFICANCES
por: Geyer, Lucas, et al.
Publicado: (2023)

p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic Significances
por: Geyer, Lucas, et al.
Publicado: (2023)

Glioblastoma Metabolism: Insights and Therapeutic Strategies
por: Bernhard, Chloé, et al.
Publicado: (2023)

TBIO-17. INTEGRATIVE ANALYSES OF BRAFv600e MUTATED GLIOMAS: FROM MOLECULAR BIOLOGY TO RADIOLOGY AND TREATMENTS
por: Lhermitte, Benoit, et al.
Publicado: (2020)

DIPG-30. HIF2 OVEREXPRESSION DICTATES AGGRESSIVENESS ADDITIONALLY TO TP53 MUTATIONS IN H3.3K27M PEDIATRIC HIGH-GRADE GLIOMAS THROUGH RAS-MAPK AND WNT/BCATENIN PATHWAYS
por: Fuchs, Quentin, et al.
Publicado: (2023)

HGG-34. A DNA DAMAGE REPAIR SIGNATURE IN PRIMARY AND RECURRENT PEDIATRIC HIGH-GRADE GLIOMAS: PROGNOSTIC AND THERAPEUTIC VALUE
por: Entz-Werle, Natacha, et al.
Publicado: (2021)

A DNA Repair and Cell Cycle Gene Expression Signature in Pediatric High-Grade Gliomas: Prognostic and Therapeutic Value
por: Entz-Werlé, Natacha, et al.
Publicado: (2021)

Hypoxia Inducible Factors’ Signaling in Pediatric High-Grade Gliomas: Role, Modelization and Innovative Targeted Approaches
por: Fuchs, Quentin, et al.
Publicado: (2020)

HGG-39. Integrative analyses of BRAFp.v600e mutated gliomas: from epigenetic to metabolic characteristics
por: Lhermitte, Benoit, et al.
Publicado: (2022)

Hypoxic Environment and Paired Hierarchical 3D and 2D Models of Pediatric H3.3-Mutated Gliomas Recreate the Patient Tumor Complexity
por: Blandin, Anne-Florence, et al.
Publicado: (2019)

DIPG-31. HIF-1A AND HIF-2A COMBINATORIAL TARGETING OR HOW TO REVERSE THEIR BALANCED ONCOGENIC IMPACT
por: Fuchs, Quentin, et al.
Publicado: (2023)

Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability
por: Pierrevelcin, Marina, et al.
Publicado: (2020)

HGG-36. HIF-2: A NEW DRUG TARGET IN PEDIATRIC HIGH-GRADE GLIOMA WITH PROMISING PRECLINICAL RESULTS
por: Fuchs, Quentin, et al.
Publicado: (2020)

Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin
por: Sani, Saidu, et al.
Publicado: (2022)

SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers
por: Jannier, Sarah, et al.
Publicado: (2020)

Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition
por: Nguyen, Aurélia, et al.
Publicado: (2017)

Together Intra-Tumor Hypoxia and Macrophagic Immunity Are Driven Worst Outcome in Pediatric High-Grade Osteosarcomas
por: Nazon, Charlotte, et al.
Publicado: (2022)

Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse
por: Nguyen, Aurelia, et al.
Publicado: (2013)

Impact of Chromatin Dynamics and DNA Repair on Genomic Stability and Treatment Resistance in Pediatric High-Grade Gliomas
por: Pinto, Lia, et al.
Publicado: (2021)

Bone metastases from a 1p/19q codeleted and IDH1-mutant anaplastic oligodendroglioma: a case report
por: Burgy, Mickaël, et al.
Publicado: (2019)

Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity
por: Cruz Da Silva, Elisabete, et al.
Publicado: (2022)

Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology
por: Sabo, Amelia-Naomi, et al.
Publicado: (2021)

How SARS-CoV-2 is forcing us to reconsider and reorganize our daily neurosurgical practice
por: Chibbaro, S., et al.
Publicado: (2020)

Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells
por: Reita, Damien, et al.
Publicado: (2019)

Effect of an intraoperative periradicular application of platelet-rich fibrin (PRF) on residual post-surgical neuropathic pain after disc herniation surgery: study protocol for NeuroPRF, a randomized controlled trial
por: Todeschi, Julien, et al.
Publicado: (2023)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

BRAF-mutant hematopoietic malignancies
por: Abdel-Wahab, Omar, et al.
Publicado: (2014)

Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors
por: Schaffner, Florence, et al.
Publicado: (2013)

Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers
por: Mercier, Marie-Cécile, et al.
Publicado: (2017)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
por: Reita, Damien, et al.
Publicado: (2021)

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
por: Reita, Damien, et al.
Publicado: (2022)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma
por: Burgy, Mickaël, et al.
Publicado: (2021)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

Investigating the real impact of COVID-19 pandemic on the daily neurosurgical practice?
por: Dannhoff, G., et al.
Publicado: (2021)

Targeting mutant BRAF in colorectal cancer
por: Carroll, David, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_aebq8eg4u4reh0qrn8s73ql3qo